Epidemiologic and Clinical Characteristics of Heart Transplant Recipients During the 2019 Coronavirus Outbreak in Wuhan, China: A Descriptive Survey Report
Overview
Authors
Affiliations
Background: The epidemiologic and clinical characteristics of heart transplant (HTx) recipients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic remains unclear. We studied the characteristics of HTx recipients from December 20, 2019, to February 25, 2020, in an effort to understand their risk and outcomes.
Methods: All accessible HTx recipients were included in this single-center retrospective study. We collected information on the recipients using a web-based questionnaire as well as the hospital database.
Results: We followed 87 HTx recipients (72.4% were men, and the average age was 51 years). A total of 79 recipients resided in Hubei, and 57 recipients had a Wuhan-related history of travel or contact. Most took precautionary measures while in contact with suspicious crowds, and 96.6% of the families and communities undertook prevention and quarantine procedures. Four upper airway infections were reported, and 3 of them tested negative for SARS-CoV-2 (the fourth recovered and was not tested). All cases were mild and successfully recovered after proper treatment. Laboratory results of 47 HTx cases within the last 2 months were extracted. Of these, 21.3% of recipients had pre-existing lymphopenia, and 87.2% of recipients had a therapeutic concentration of tacrolimus (5-12 ng/ml). Liver and kidney insufficiency was seen in 5 and 6 recipients, respectively.
Conclusion: HTx recipients who practiced appropriate prevention measures had a low rate of infection with SARS-CoV-2 and transition to the associated disease COVID-19. These early data will require confirmation as the pandemic establishes around the world.
COVID-19 Pandemic and Cardiovascular Disease.
Rali A, Sauer A US Cardiol. 2024; 14:e01.
PMID: 39720444 PMC: 11664787. DOI: 10.15420/usc.2020.14.
[SARS-CoV-2 Infection in Heart Transplant Recipients].
Yarahuaman-Mora J, Munoz-Moreno J, Alarco-Leon W Arch Peru Cardiol Cir Cardiovasc. 2024; 1(2):117-123.
PMID: 39588391 PMC: 11587597. DOI: 10.47487/apcyccv.v1i2.56.
Bai F, Pu J, Che W, Chen J, Chen M, Chen W Cardiol Plus. 2023; 8(2):82-102.
PMID: 37486153 PMC: 10358441. DOI: 10.1097/CP9.0000000000000043.
How the Heart Was Involved in COVID-19 during the First Pandemic Phase: A Review.
Canalella A, Vitale E, Vella F, Senia P, Cannizzaro E, Ledda C Epidemiologia (Basel). 2022; 2(1):124-139.
PMID: 36417195 PMC: 9620895. DOI: 10.3390/epidemiologia2010011.
Cardiovasc Res. 2021; 118(7):1618-1666.
PMID: 34864876 PMC: 8690236. DOI: 10.1093/cvr/cvab343.